Abstract: The invention relates to a composition for the treatment and/or prevention of infection by gastrointestinal pathogens, in particular Helicobacter pylori and/or a disease associated with infection by said gastrointestinal pathogen in mammals.

Abstract: The present invention relates to a method and a composition for feeding low birthweight infants (LBW infants), very low birthweight infants (VLBW infants), extremely low birthweight infants (ELBW infants) and preterm infants for improving oral tolerance.

Abstract: An oligosaccharide mixture based on oligosaccharides from one or several animal milks composed of two or more monosaccharide units. The oligosaccharide mixture comprises at least two oligosaccharide fractions which are each composed of at least two different oligosaccharides. Lactose does not pertain thereto and the total spectrum of the oligosaccharides in the oligosaccharide mixture differs from those present in animal milk or animal milks, wherefrom the oligosaccharide fractions are extracted and that a) if the oligosaccharides are extracted from only one animal milk, the proportion of neutral oligosaccharides to acidic oligosaccharides is 90-60:10-40 weight %, or b) if the oligosaccharides are extracted from at least two animal milks, the oligosaccharides extracted from two different animal milks each make up 10 weight % of the total amount of oligosaccharides present in the oligosaccharide mixture. The oligosaccharide mixture approximates human milk with respect to its positive properties.

Abstract: The present invention relates to a method and a composition for feeding low birthweight infants (LBW infants), very low birthweight infants (VLBW infants), extremely low birthweight infants (ELBW infants) and preterm infants for improving oral tolerance.

Abstract: The invention relates to a composition for the treatment and/or prevention of infection by gastrointestinal pathogens, in particular Helicobacter pylori and/or a disease associated with infection by said gastrointestinal pathogen in mammals.

Abstract: The invention relates to the use of a peptide mixture comprising peptides with a molecular weight from 1000 to 5000 Daltons for the prevention and/or treatment of tumour diseases, of diseases which are associated with a development disorder of the immune system, of diseases of the immune system, of autoimmune reactions, of allergies and of inflammation in man, a protein component which contains such a peptide mixture and a formula food containing this peptide mixture. The peptides are preferably obtained from non-human proteins suitable for nutritional purposes, in particular by the enzymatic or hydrolytic cleavage of these proteins.

Abstract: The invention relates to exsulins or insulin mimetic amino acid sequences with a molecular weight of up to 55,000 daltons and with 1 to 50 basic units of following Formula (1): [?] L,V,I,A]-X1—X2-[L,V,I,A]-[D,E]-[N,Q,M]-X3—[C,H]—X4 [?], whereby; [L,V,I,A], [D,E], [N,Q,M], [C,H] and X1 to 4 represent peptidically linked amino acids; [L,V,I,A] represents leucine (L), valine (V), isoleucine (I) or alanine (A); [D,E] represents asparaginic acid (D) or glutamic acid (E); [N,Q,M] represents asparagine (N), glutamine (Q) or methionine (M); [C,H] represents cysteine (C) or histidine (H); both groups [L,V,I,A] in a basic unit can be identical or different; X1, X2, X3 and X4 represent any type of amino acid and the four amino acids X1 to 4 in a basic unit can be identical or different.

Abstract: A thymus growth stimulating baby food is provided, substantially composed of a fat component, as well as a carbohydrate component and a protein component of animal or vegetable or animal and vegetable but not human origin, whereby the protein component is composed of intact proteins, hydrolyzed proteins, peptides or the constituents thereof, or of amino acids or a mixture thereof not bound to peptides or proteins. This type of baby food is characterized in that the total amount of arginine is at least 3.7 g per 100 g of the amino acids present in toto, and that it contains zinc (calculated as elementary zinc) in an amount of at least 40 mg per 100 g of the amino acids present in toto.

Abstract: The invention relates to products for complete nutrition of infants. The products are characterized by the type and amount of protein and carbohydrate and the increased levels of folic acid, vitamin B6 and vitamin B12 or their functional equivalents. These products improve feelings of well-being of infants, especially those of young age, and are useful in the treatment and prevention of diseases that are associated with disorders of serotonin- and melatonin metabolism.

Abstract: The invention relates to an oligosaccharide mixture based on oligosaccharides produced from one or several animal milks and which are composed of two or more monosaccharide units. Said oligosaccharide mixture is characterized in that it comprises at least two oligosaccharide fractions which are each composed of at least two different oligosaccharides.

Abstract: The invention relates to the use of a protein component based on conventional proteins used for the production of foods, at least 20 wt-% thereof having a phosphate residue, which is covalently bound to the protein, whereby 50 to 100 wt-% of the proteins including at least one covalently bound phosphate residue, are subjected to a dephosphorylation reaction wherein 20 to 100% of the covalently bound phosphate residues were removed, for a treatment of adult and adolescent patients, as well as of babies and small children suffering from a disturbed gastrointestinal motility and of reflux-predisposed patients. The use of said protein component not only allows for a sufficient protein supply but it also passes rapidly through the stomach and prevents the stomach contents from flowing back into the oesophagus.

Abstract: The invention relates to the use of threonine for the treatment of phenylketonuria. The invention is based on the surprising discovery that the concentration of phenylalanine in the plasma of PKU patients can be reduced by additional doses of threonine. The object of the invention is therefore an composition for dietetic or pharmaceutical use in phenylketonuria, which composition contains at least 8 g threonine per 100 g amino acids. This composition may consist of foods, in particular formula foods and PKU dietetic products.

Abstract: A protein composition and a baby food (infant formula) containing this are provided. The protein composition is characterised in that it contains at least 15 wt % (based on the total amount of the proteins) modified proteins, the course of whose digestion is slowed compared to the unmodified, normal proteins serving as starting materials. Such a protein composition and a baby food containing this create just as good metabolic conditions for the normal development of a child as feeding with human milk proteins.

Abstract: A whey protein dominant baby food is prepared that may contain hydrolysed food with a reduced threonine content. This food can be obtained by adding glycomacropeptide-free or glycomacropeptide-reduced whey powder and/or whey protein concentrate as the whey proteins usually used in the production of milk baby food.